A phase II trial of preoperative mitomycin, cisplatin and 5-fluorouracil in adenocarcinoma of the oesophagus
| Autor: | S.J. Darnton, D. R. Ferry, M.H. Cullen, A.G. Casson |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Male
Antimetabolites Antineoplastic medicine.medical_specialty Esophageal Neoplasms medicine.medical_treatment Antineoplastic Agents Adenocarcinoma Preoperative care Gastroenterology Mitomycins Cause of Death Internal medicine Antineoplastic Combined Chemotherapy Protocols Preoperative Care medicine Humans Radiology Nuclear Medicine and imaging Survival rate Lymph node Neoadjuvant therapy Aged Neoplasm Staging Aged 80 and over Cisplatin Chemotherapy Antibiotics Antineoplastic business.industry Remission Induction Leukopenia Middle Aged medicine.disease Neoadjuvant Therapy Surgery Esophagectomy Survival Rate medicine.anatomical_structure Oncology Chemotherapy Adjuvant Fluorouracil Female business medicine.drug |
| Zdroj: | Clinical Oncology. 10:372-376 |
| ISSN: | 0936-6555 |
| DOI: | 10.1016/s0936-6555(98)80032-0 |
| Popis: | The effect of neoadjuvant chemotherapy in patients with apparently operable adenocarcinoma of the oesophagus has been investigated. Two courses of mitomycin, cisplatin and 5-fluorouracil (MCF) were given, followed by a radiological evaluation of response. Twenty-two of 25 patients completed both courses. Two showed a complete response and 12 a partial response. There was a pathological complete response of the primary tumour in only one patient (although there was residual secondary tumour in a local lymph node). The main toxicity was myelosuppression, with 9/22 patients having the second chemotherapy course delayed. There were three sudden deaths, one due to a pulmonary embolus and two due to complications of infections. Twenty-one patients underwent surgical exploration; there were 18 resections. Although the radiological response rate of MCF (14/25; 56%; 95% CI 37-75) appeared promising, there were no pathological complete responders. Further Phase II trials are needed to identify more efficacious agents and regimens that will yield a pathological response rate of at least 10%, before proceeding to randomized trials of neoadjuvant chemotherapy for adenocarcinoma of the oesophagus. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect